Intra-tumoral injection of CpG results in the inhibition of tumor growth in murine Colon-26 and B-16 tumors

Biotechnol Lett. 2003 Jan;25(2):149-53. doi: 10.1023/a:1021927621813.

Abstract

Direct tumor injections of CpG (ODN #1826) into murine tumors markedly suppressed the tumor growth and increased the survival of the mice. Tumor growth was reduced by 60-67% in Colon Tumor 26 (CT-26) and B-16 melanoma tumors treated with CpG as compared to untreated one. In CT-26 and B-16 tumors treated with CpG, the average survival of the animals were prolonged to 26 and 28 d as compared to 16 and 18 d in control respectively. Long-term surviving animals in CT-26 tumor groups were also protected from a subsequent injection of a lethal dose of tumor cells. In the present study, effect of CpG was mediated through CD8+ T cells, as their depletion resulted in the abrogation of the therapeutic effects of the CpG. It suggests that direct tumor injection might be a simple means of achieving a clinical response in cancer patients.

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Division / drug effects
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / immunology
  • Colonic Neoplasms / physiopathology*
  • DNA / administration & dosage*
  • DNA / immunology
  • Female
  • Injections, Intralesional
  • Melanoma / drug therapy*
  • Melanoma / immunology
  • Melanoma / physiopathology*
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Neoplasm Staging / methods
  • Neoplasm Transplantation
  • Oligodeoxyribonucleotides
  • Tumor Cells, Cultured / drug effects
  • Tumor Cells, Cultured / immunology

Substances

  • CpG ODN 1826
  • Oligodeoxyribonucleotides
  • DNA